All In Biotech

NDA 019670 · Bayer Healthcare LLC

Claritin-D

Loratadine, Pseudoephedrine Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Nov 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Nov 14, 1994

Approved uses

3

Original approval plus efficacy supplements

Registered trials

89

27 Phase 3, 6 recruiting

FAERS reports

6,976

1,256 serious, 72 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: sneezing itchy, watery eyes runny nose itching of the nose or throat temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 30, 2004 Supplement 19 · Efficacy LabelLetter
  • Nov 27, 2002 Supplement 18 · Efficacy ReviewLetter
  • Nov 14, 1994 Original approval · Type 4 - New Combination
1 products under this application
  • CLARITIN-D · LORATADINE 5MG; PSEUDOEPHEDRINE SULFATE 120MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Loratadine" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,537
  • insomnia677
  • drug effect decreased395
  • product use issue381
  • dizziness324
  • somnolence259
  • headache252
  • nausea231
  • fatigue219
  • dyspnoea203
  • feeling abnormal193
  • palpitations186

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004114
2005114
200695
200784
200881
2009107
2010106
2011127
2012325
2013417
20141,591
2015702
2016738
2017601
2018330
2019307
2020244
202181
2022205
2023301
2024109
2025121
202676

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 388 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.